

DRUG METABOLISM AND DISPOSITION

A Publication of the American Society for Pharmacology and Experimental Therapeutics

August 2018

Vol. 46, No. 8

CONTENTS

MINIREVIEW

Cytochrome P450 2J2: Potential Role in Drug Metabolism and Cardiotoxicity. *Meetal Solanki, Amy Pointon, Barry Jones, and Karl Herbert* . . . **1053**

The Drug-Drug Interaction Potential of Antiviral Agents for the Treatment of Chronic Hepatitis C Infection. *Kimberly L. Garrison, Polina German, Erik Mogalian, and Anita Mathias* . . . **1212**

ARTICLES

□ An Assessment of the In Vitro Inhibition of Cytochrome P450 Enzymes, UDP-Glucuronosyltransferases, and Transporters by Phosphodiester- or Phosphorothioate-Linked Oligonucleotides. *Faraz Kazmi, Phyllis Yerino, Chase McCoy, Andrew Parkinson, David B. Buckley, and Brian W. Ogilvie* . . . **1066**

Further Studies to Support the Use of Coproporphyrin I and III as Novel Clinical Biomarkers for Evaluating the Potential for Organic Anion Transporting Polypeptide 1B1 and OATP1B3 Inhibition. *Hong Shen, Lisa Christopher, Yurong Lai, Jiachang Gong, Hamza Kandoussi, Samira Garonzik, Vidya Perera, Tushar Garimella, and W. Griffith Humphreys* . . . **1075**

Functional Characterization of 21 Allelic Variants of Dihydropyrimidine Dehydrogenase Identified in 1070 Japanese Individuals. *Eiji Hishinuma, Yoko Narita, Sakae Saito, Masamitsu Maekawa, Fumika Akai, Yuya Nakanishi, Jun Yasuda, Masao Nagasaki, Masayuki Yamamoto, Hiroaki Yamaguchi, Nariyasu Mano, Noriyasu Hirasawa, and Masahiro Hiratsuka* . . . **1083**

Xanthates: Metabolism by Flavoprotein-Containing Monooxygenases and Antimycobacterial Activity. *Stanislav G. Yanev, Tsveta D. Stoyanova, Violeta V. Valcheva, and Paul R. Ortiz de Montellano* . . . **1091**

□ Multidrug Resistance Protein 1 (MRP1/ABCC1)-Mediated Cellular Protection and Transport of

Methylated Arsenic Metabolites Differs between Human Cell Lines. *Mayukh Banerjee, Gurnit Kaur, Brayden D. Whitlock, Michael W. Carew, X. Chris Le, and Elaine M. Leslie* . . . **1096**

□ CYP2D6 Allelic Variants *34, *17-2, *17-3, and *53 and a Thr309Ala Mutant Display Altered Kinetics and NADPH Coupling in Metabolism of Bufuralol and Dextromethorphan and Altered Susceptibility to Inactivation by SCH 66712. *Sarah M. Glass, Cydney M. Martell, Alexandria K. Oswald, Victoria Osorio-Vasquez, Christi Cho, Michael J. Hicks, Jacqueline M. Mills, Rina Fujiwara, Michael J. Glista, Sharat S. Kamath, and Laura Lowe Furge* . . . **1106**

□ Age-Related Changes in Expression and Activity of Human Hepatic Mitochondrial Glutathione Transferase Zeta1. *Guo Zhong, Margaret O. James, Marci G. Smeltz, Stephan C. Jahn, Taimour Langae, Pippa Simpson, and Peter W. Stacpoole* . . . **1118**

Fluorocholeline Transport Mediated by the Organic Cation Transporter 2 (OCT2, SLC22A2): Implication for Imaging of Kidney Tumors. *Michele Visentin, Angelo Torozzi, Zhibo Gai, Stephanie Häusler, Chao Li, Christian Hiller, Peter H. Schraml, Holger Moch, and Gerd A. Kullak-Ublick* . . . **1129**

Nitidine Chloride Is a Mechanism-Based Inactivator of CYP2D6. *Xu Mao, Zixia Hu, Qian Wang, Na Zhang, Shenzi Zhou, Ying Peng, and Jiang Zheng* . . . **1137**

□ Regulation of Cytosolic Sulfotransferases in Models of Human Hepatocyte Development. *Sarah Dubaisi, Kathleen G. Barrett, Hailin Fang, Jorge Guzman-Lepe, Alejandro Soto-Gutierrez, Thomas A. Kocarek, and Melissa Runge-Morris* **1146**

S-Enantiomer of 19-Hydroxyeicosatetraenoic Acid Preferentially Protects Against Angiotensin II-Induced Cardiac Hypertrophy. *Sherif M. Shoieb and Ayman O. S. El-Kadi* . . . **1157**

Continued on next page

- Development and Characterization of a Human Hepatocyte Low Intrinsic Clearance Assay for Use in Drug Discovery. *Paul Lancett, Beth Williamson, Patrick Barton, and Robert J. Riley* **1169**
- Simultaneous Assessment of Transporter-Mediated Drug-Drug Interactions Using a Probe Drug Cocktail in Cynomolgus Monkey. *Rachel E. Kosa, Sarah Lazzaro, Yi-an Bi, Brendan Tierney, Dana Gates, Sweta Modi, Chester Costales, A. David Rodrigues, Larry M. Tremaine, and Manthena V. Varma* **1179**
- Three Faces of Mercaptopurine Cytotoxicity In Vitro: Methylation, Nucleotide Homeostasis, and Deoxythioguanosine in DNA. *Sally A. Coulthard, Sarah McGarrity, Kalvin Sahota, Philip Berry, and Chris P. F. Redfern* **1191**
- Application of Physiologically Based Pharmacokinetic Modeling in Understanding Bosutinib Drug-Drug Interactions: Importance of Intestinal P-Glycoprotein. *Shinji Yamazaki, Cho-Ming Loi, Emi Kimoto, Chester Costales, and Manthena V. Varma* **1200**
- PBDEs Altered Gut Microbiome and Bile Acid Homeostasis in Male C57BL/6 Mice. *Cindy Yanfei Li, Joseph L. Dempsey, Dongfang Wang, SooWan Lee, Kris M. Weigel, Qiang Fei, Deepak Kumar Bhatt, Bhagwat Prasad, Daniel Raftery, Haiwei Gu, and Julia Yue Cui* **1226**
- Consequences of Phenytoin Exposure on Hepatic Cytochrome P450 Expression during Postnatal Liver Maturation in Mice. *Stephanie C. Piekos, Liming Chen, Pengcheng Wang, Jian Shi, Sharon Yaqoob, Hao-Jie Zhu, Xiaochao Ma, and Xiao-bo Zhong* **1241**

ERRATUM

- Correction to “Structure-Activity Relationships of the Main Bioactive Constituents of *Euodia rutaecarpa* on Aryl Hydrocarbon Receptor Activation and Associated Bile Acid Homeostasis”. **1190**

Supplemental material is available online at <http://dmd.aspetjournals.org>.

About the cover: DPD structural analysis. (A) Diagram showing the overall structure of human DPD, FAD, NADPH, FMN, and FeS clusters. 5-Fluorouracil is colored yellow, FAD and FMN are colored green, NADPH is colored blue, and the Fe-S clusters are shown as gray spheres. (B) The DPD subunit. See the article by Hishinuma et al. (<https://doi.org/10.1124/dmd.118.081737>).